The IQS Business Foundation has recently added INKE, SA, a fine chemical company within the pharmaceutical sector based in Barcelona, as a new member.
The IQS Business Foundation has recently added INKE, SA, a fine chemical company within the pharmaceutical sector based in Barcelona, as a new member. The company's membership in the IQS Business Foundation was formalized through an institutional event held on 7 November at IQS. On behalf of Inke, the event was attended by Miquel Bachs, managing director, and Dr Pere Dalmases, R&D director, also an IQS alumnus and PhD in chemical engineering. On behalf of IQS, Dr Salvador Borrós, Director of IQS, and Rosa Curt, Director of the IQS Business Foundation, were present.
Inke was founded in 1980 and is dedicated to the development and manufacture of active pharmaceutical ingredients (APIs) with complex synthesis processes, mainly for use in respiratory therapies. In fact, the company boasts more than 20 years of experience in micronization and particle engineering with complex synthesis processes and holds a great deal of regulatory knowledge. Some of the products that Inke offers include arformoterol, formoterol, glycopyrrolate, indacaterol, salmeterol, tiotropium, and vilanterol. Based in Barcelona, it sells its APIs to more than 35 countries across Europe and the United States, Japan, South Korea, and China. With sales close to 30 million euros, it is the benchmark company for inhalation APIs.